Inactive Instrument

Flamel Technologies S.A. (ADR) Stock price Nasdaq

Equities

US3384881096

Pharmaceuticals

End-of-day quote Nasdaq
- USD 0.00% Intraday chart for Flamel Technologies S.A. (ADR)
Sales 2024 * 167M Sales 2025 * 301M Capitalization 1.53B
Net income 2024 * -33M Net income 2025 * 91M EV / Sales 2024 * 9.53 x
Net Debt 2024 * 66.33M Net cash position 2025 * 5.71M EV / Sales 2025 * 5.05 x
P/E ratio 2024 *
-37.3 x
P/E ratio 2025 *
21.1 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 39.35%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 57 17-01-02
Director of Finance/CFO 59 19-12-01
Chief Operating Officer - 14-08-31
Members of the board TitleAgeSince
Director/Board Member 55 18-11-30
Chief Executive Officer 57 17-01-02
Director/Board Member 72 19-12-04
More insiders
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's lead product, LUMRYZ, is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME and MEDUSA. Its MICROPUMP technology allows for the development of modified release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
More about the company
  1. Stock
  2. Equities
  3. Stock Avadel Pharmaceuticals plc
  4. Stock Flamel Technologies S.A. (ADR) - Nasdaq